In an in vivo experiment of cholestatic liver disease, scoparone inhibited liver inflammation and fibrosis, improved cholestasis, and promoted the recovery of liver injury by upregulating the expression of farnesoid X receptor/bile salt export pump (FXR/BSEP) pathway (Yuan et al., 2020). Here, NR1H4 is linked to Cholestatic liver disease.